Latest / The Dr. Randi Show / The Injectable Breakthrough for Facial Changes After Medical Weight Loss — Dr. Rui Avelar

Transcript

The Injectable Breakthrough for Facial Changes After Medical Weight Loss — Dr. Rui Avelar · The Dr. Randi Show

0:03
The views expressed in this podcast are for informational
0:06
purposes only and do not constitute medical advice.
0:09
This episode of The Doctor Randy Show is proudly sponsored by New
0:13
Beauty, the ultimate authority in beauty and aesthetics.
0:17
Whether you're. Looking for the latest
0:18
innovations, expert insights or trusted recommendations?
0:22
New Beauty is your go to source. Visit newbeauty.com to stay
0:27
ahead of the trends and discover what's next in beauty.
0:30
Now let's get into the episode. Hello everyone, and welcome to
0:34
the Doctor Randy show. I'm Doctor Randy and here's
0:37
where we explore the intersection of medicine, beauty
0:41
and innovation. Today we have a very special
0:44
guest. He is the Chief Medical Officer
0:47
at Evillis. He's behind the launch of
0:49
Evalise, the first major filler innovation in over a decade, and
0:54
he's rewriting the playbook on how we age beautifully.
0:57
Please welcome Doctor Rui Avalar.
1:01
Thank you, Doctor Mandy, so excited to have you on.
1:04
And you are right in the center of the most exciting launches in
1:08
our industry. So it's an honor to have you
1:10
here. And I'm just going to jump right
1:12
in and get started with the questions, if that's OK with
1:14
you. OK, so for anyone that has not
1:19
heard the word Evolis yet, we've all heard Evolis, right?
1:22
But for those who who are hearing the name Evolis and
1:25
hearing about it for the first time, how would you describe it
1:28
in simple terms? Well, and first of all, it's a
1:31
hydronic acid Jelly. When we talk about fillers, it's
1:34
such a broad category. We've actually were bold enough
1:38
to start a campaign, drop the F word and instead of talking
1:42
about fillers, which you know, has all sorts of components, the
1:46
evalise line is actually made of hyaluronic acid.
1:49
And as we all know, we're loaded with hyaluronic acid.
1:53
It's in your skin, it's in your joints.
1:55
That's the way we retain water and moisture and it has lots.
1:58
And now it's kind of on your skin's cosmosuticals that you
2:01
can get. And fundamentally, the best way
2:04
I would describe the evalise line is we think about
2:08
hyaluronic acid. I just think we did a really
2:11
good job preserving the natural structure that AJ and one thing
2:15
that that people forget is Mother Nature and designed
2:19
hyaluronic acid. And it's so highly preserved
2:23
across all sorts of species, like those cute little puppies
2:27
that you see on the street, same HA as you.
2:30
And when you manufacture these gels, there are steps that can
2:35
actually change what that HA looks like.
2:38
So I think in a nutshell, the the magic if you will behind
2:42
Evelise is our manufacturing process.
2:44
I just think we did a better job of preserving that natural HA
2:47
structure. Fantastic.
2:50
And I have always been a big fan of filler.
2:54
Many people start younger. I know this is a different form,
2:57
but this is, you know, what we've known I started later in
3:00
life. I'm 54, started about 10 years
3:03
ago. And it really is just amazing
3:06
what it does to your skin, how it's able to plump things up and
3:11
really give that youthful look again.
3:13
So we're very excited to to hear about this.
3:17
One of the things that I'm intrigued about when reading
3:20
about this and studying and prepping for the show, when it
3:24
comes to traditional injectables, people say I don't
3:28
want to look overdone and that's always been my concern.
3:31
In fact, when I go for my little pick me up, I go every three
3:35
months. Instead of drawing that out and
3:38
doing a lot at once, I go every three months so that I can have
3:41
just the right amount and not too much at once.
3:44
So people don't want to look overdone.
3:46
So how does evalise keep results natural?
3:50
You've you're raising a whole bunch of points that are so
3:53
important. And if I can just kind of take a
3:56
step back from the hyaluronic acid injectable and just look at
4:00
line of toxins, for instance, we kind of went through that where
4:03
there was a stage when it was introduced that people you can
4:07
argue were overdone. I mean, the aesthetic outlook
4:10
was I want to look completely annihilated.
4:12
I want absolutely nothing to move, which is a very artificial
4:15
look. And maybe in some demographics,
4:18
parts of the world, we may still want that.
4:20
But for the most part, it's now recognized that that was an
4:23
overdone look. And what we've learned with
4:25
botulinum toxin injectables is you're looking for something
4:28
that gives a more natural look. And I think there's a parallel
4:31
with all use the term fillers. We need to be somewhat
4:35
responsible. They do these marvelous things,
4:37
but you can overdo it and you can overfill, and I think the
4:41
world has seen that. Hence we're seeing this term.
4:43
We don't want to look overfilled.
4:45
And I think what you're bringing up is incredibly important.
4:48
We see a shift where people just want to look natural.
4:51
They want to age gracefully or stave off the aging process as
4:54
opposed to looking artificial. Hyaluronic acid injectables are
4:57
a great way of doing that, again, because it's a natural
5:01
compound that you have, and we know that when we inject that
5:04
you can actually even stimulate some of your own collagen.
5:07
How does Evelise do it? Well, as I mentioned to you, one
5:10
of the things about the at least technology is we do a really
5:14
good job preserving those HA filaments.
5:18
And what we saw in clinical studies was that you always seem
5:23
to require less material or less HA injectable to get an outcome.
5:30
So less seems to give you more efficient gel, so you need less
5:35
of it. So in this theme where we want
5:37
to look natural, being able to get a lift or correction with
5:40
less material, I think plays really well into that.
5:44
That's great. I think we're ready as consumers
5:47
in the marketplace for something new and something that is fresh
5:51
and we're looking for the new technology.
5:53
So very excited about this and to see the different results,
5:58
what people are achieving with it.
6:00
So very excited about that. And what is the big difference
6:05
that people will see that people like myself who go for
6:08
traditional filler and have been for 10 years, what is the
6:12
biggest difference that patients will notice when comparing the
6:17
two for an injector? The thing that we hear the most
6:21
is that I just seem to get more correction with less material
6:25
for the patient. What we tend to hear is I get a
6:28
very natural outcome in and the material just seems very smooth.
6:32
We also hear that from the injectors that when they
6:34
actually use the material seems to be very smooth to integrate
6:37
well into the tissue and that patient feedback is almost like
6:41
it seems to be soft, feels quite natural.
6:44
The other really big thing is sometimes when you inject the
6:48
gel it has a lot of free hyaluronic acid in it.
6:52
So what that means is you have to over inject and then over the
6:56
next four to six weeks a lot of that free AJ goes away and then
7:00
you settle into your natural outcome.
7:03
Some gels absorb a lot of water after injecting.
7:06
So as a patient you may be under corrected simply because you
7:10
need to accommodate that swelling period.
7:13
So for the next, you know, two 3-4 weeks, the product will
7:16
swell and then you'll get a correction.
7:18
The feedback that we've been getting from the injectors and
7:22
from the folks who've used it is you inject to correction.
7:26
You don't have to over inject because free AJ is going to go
7:28
away. You don't have to under correct
7:29
because it's going to swell. The result you have when you're
7:33
at the injector's office is the result that you will get.
7:36
And I'm talking a bell curve, right?
7:38
There's always exception, everything that's phenomenal
7:42
because that is something that I battle, right is so sometimes I
7:46
come home and I'm like, I love the way it looks.
7:49
And then two weeks later it deflates.
7:52
So then you're like, oh, now I need a little bit more.
7:54
So that's a great thing that we can look forward to.
7:58
And I have a question. Are there certain areas of the
8:01
face related to what you just said that this is more
8:06
recommended for than others? Or can it be used anywhere on
8:09
the face? So it depends on which region
8:13
you live in. Evelyst is a global company and
8:15
we have the rights to these itching injectables in the
8:18
United States and in Europe. So in Europe we've launched a
8:21
full portfolio of materials. Some products are very
8:25
structured and can be used in the mid phase to build a
8:28
cheekbone, take volume. Some products are really soft,
8:31
like the smooth product, so soft that you can use it in those,
8:34
you know, those lipstick lines you get around the mouth of
8:37
those fine lines. You can put it very, very
8:40
superficial there. Or if you're looking for a soft
8:42
look in the lips, you can use that smooth product.
8:45
And it's been used in Europe that way.
8:47
There's a product that's kind of in the middle from rheological
8:50
perspective, and that's called the form that has some
8:53
structure, yet it's soft. So you can put it in these deep
8:56
wrinkles and folds like the nasolabial folds or the fold you
8:59
can get under here or those marionette lines that come down
9:02
here. And then there's a lip specific
9:05
product in Europe that is kind of has some structure and has
9:08
some volume. In the United States, the two
9:11
main products that are launching right now, we're kind of the
9:13
most utilitarian. The form is the one that fits in
9:16
the middle and has some structure and some softness and
9:20
that could be put in kind of deeper wrinkles and folds like
9:24
the nasolabial folds, but you can put it in that supplemental
9:28
fold or the Marinette lines. And then the smooth product, it
9:32
just has a different attribute. It's almost a little bit more
9:34
liquid like you can also use it in that kind of indication.
9:37
And then just on Friday, we just released the the data that our
9:42
most structural product did very well and we just filed that with
9:46
the FDA. So that products called
9:48
sculpting that we're looking to launch that in the United States
9:50
in the second-half of 2026. Excellent, excellent.
9:54
Well, congratulations. It sounds like a full suite of
9:57
products that we can rely on over time.
9:59
So that sounds great. And for someone who has never
10:03
had an injectable hyaluronic acid or filler in the past, why
10:09
do you think this might be a good entry point for them?
10:12
Well, the hyaluronic acid gels again incur the wonderful thing
10:18
about is they're natural in the sense that the backbone is
10:21
natural. Hyaluronic acid is kind of a
10:23
natural compound. So that makes it a good end.
10:27
We know that they're highly efficacious, so that's always a
10:30
good thing. And then you never want somebody
10:33
to have an adverse event. But one of the big benefits of
10:36
hyaluronic acid as compared to the other category of fillers
10:40
that people call biostimulants is if something goes wrong or if
10:45
you're not happy with the aesthetic outcome or if there's
10:47
a complication. Mother Nature also invented
10:50
hyaluronidase, which is a natural enzyme that would
10:55
dissolves and gets rid of the hyaluronic acid.
10:57
So it's the reason I think it's a great entrant is it's based on
11:03
hyaluronic acid. And if you get into any issues
11:07
that you want to get rid of it, you can get rid of it.
11:10
And there are some that are not dissolvable, right?
11:12
And I've had to have one or two things dissolved over time, but
11:16
that would make me very afraid that something would not be just
11:20
like, you know, like there is not the antidote to it.
11:23
So I think it's great that we have that option.
11:25
And that's a great feeling going into it.
11:28
You know, if it looks a certain way and you don't like it, that
11:30
you can fix it, right? And it's very easy to get it
11:33
undone. I agree with you.
11:36
So I think that to some people that are intimidated by
11:42
aesthetics or aesthetic care, how do you see Evely's fitting
11:47
into everyday self-care for those who might be intimidated
11:51
by needles or whatnot in the past?
11:53
Will there be marketing or messaging that allows us to feel
11:56
a little bit more comfortable for the everyday user?
12:00
We've tried to make it really simple.
12:02
We've tried to make things very accessible and we've obviously
12:04
tried to educate folks. So it starts with fundamentally
12:09
your product, how does it work? So on the scientific side, I've
12:12
shared with you the basic premise of it, which is built
12:15
really around natural compound. Then it behooves us to to show
12:19
clinical data that is both safe and effective.
12:22
And so those clinical trials undergo a lot of scrutiny by the
12:26
FDA form smooth or approved here.
12:28
All the products are approved in Europe right now and we have
12:31
some going through the FDA. So that's the price of
12:33
admission. As an organization, obviously we
12:36
try to make materials. You may notice Evolus does not
12:39
look pharma like. The whole platform of the
12:41
company is to try and be very user friendly, try to make
12:45
things very accessible and very easy.
12:47
I mean, I couldn't imagine a pharma going out with the slogan
12:50
don't drop the effort like we did.
12:52
We like it to be approachable. We have a group that also helps
12:56
to educate the providers because ultimately if I think about a
13:00
patient to patient pairs with a provider, an injector and really
13:05
there's a relationship that has to be built there.
13:07
They have to trust their provider and that providers is
13:11
the one that quite often will ask us a lot of information,
13:13
want training, want different sorts of information and we
13:17
provide that. So for instance, for the
13:19
injectors and the groups that we work with, we're more than happy
13:23
to provide the literature, but we also provide a great deal of
13:25
training that's really in depth. We have what's called medical
13:29
affairs clinicians that will go out and help teach you about the
13:32
product, how to inject it if you want, and give a lot of
13:35
education on the background in the anatomy so that people feel
13:39
very comfortable when they're injecting products.
13:41
Because we want our product to have a good results.
13:44
And that starts with our injectors feeling comfortable
13:46
and confident injecting it and then ultimately layers up to
13:49
patients coming in and having good experience with the police
13:51
and the providers we work with. That's wonderful because I think
13:55
that we've all heard these horror stories of injectors who
13:59
aren't properly trained. And I think that knowing that
14:03
your brand is standing behind the product and going out and
14:06
making sure that the injectors are trained, that helps us sleep
14:09
a little better at night. So that's great that you're
14:12
investing in your brand to do that.
14:15
And the patients, what are their early comments from those who
14:19
have received the treatment and maybe they've received the other
14:22
filler in the past. How are they feeling about that
14:25
and what are their reactions? Well, share a story.
14:28
I hope you won't mind me sharing this, but Doctor Doris Day is a
14:31
really well known dermatologist in Manhattan.
14:34
She's been on our show. We love her and I love her, but
14:38
just because she's so straightforward and she's just
14:41
so blunt and she's incredibly smart and she's a incredibly
14:45
skilled injector. So she and I did a meeting with
14:49
some journalists and she was doing the clinical side and I
14:52
was doing kind of the scientific geeky side.
14:54
And one of the journalists asks like, how do the patients feel
14:58
about it? And she shares the story.
15:00
She says, look, I'm self professed very conservative.
15:04
I do not like jumping into new products and I would rather wait
15:09
and see how things play out. And then she said, but I played
15:13
with the gels and it was so differentiate.
15:15
This was so different, and we had the clinical data, but she
15:19
said it was different enough that it was intriguing enough
15:22
that she thought, I'm going to break my old rules and jump in.
15:26
So the next step is injecting a patient.
15:28
And she said the first patient that she injected, of course, is
15:32
going to have an influence on how you think of it, right?
15:34
Does it go well? Does it go poorly?
15:36
And she shared that she injected a patient who was always willing
15:41
to try the new thing. So she just said, look, I have
15:45
this brand new gel. I've never injected.
15:47
I have no experience with it. Do you want to try and patients
15:49
as sure. So she injected her and then at
15:53
this point when we're together, she says, and this is the text I
15:56
got from my patient, whatever you injected was magic period.
16:00
I love you, period. So she said you got a lot of
16:05
yeah, there's nothing scientific behind that.
16:07
But I think the underlying most important thing is the patient
16:11
is always right. The subject's always right.
16:13
We always want to do our patients well.
16:15
But to get that kind of feedback was really kind of heartfelt.
16:19
That's great. And to have Doris Day at the
16:22
helm of that, that's amazing. She's also an incredibly skilled
16:26
person, so I think it's almost as important.
16:29
Yeah, she has her own technique that she uses for all of this,
16:33
so not many do. And then I really think that she
16:36
takes things to the next level. So are you planning to partner
16:41
this with your neurotoxin Juvo, or come up with the way that
16:44
they complement each other for the consumer?
16:48
Yeah, so another great question. As an organization, obviously
16:51
we've really targeted the practices we partner with.
16:55
Again, we want them to be empowered and we're now we're
16:58
starting to go out to the consumer.
17:01
It's a natural coupling to have our neurotoxin JAVO with our
17:05
injectable HAF Elise, tremendous amount of overlap with the
17:08
patients. So it's an absolute natural one.
17:11
And then you know the other interesting thing about the F
17:13
Elise line is it's the only filler on label that can be used
17:18
with GLP 1 weight loss. So if we have that in our
17:22
patient labeling, that's almost a third dimension if you will,
17:25
but pairing it with our neurotoxin absolutely.
17:28
And we're that neurotoxin Javo is now you know, since we've
17:32
almost since we kind of relaunched, it's been the
17:34
fastest growing neurotox release last three or four years.
17:39
So let's go back to what you just said about the GLP ones.
17:42
We have a lot of our listeners and viewers are taking GLP ones
17:47
or interested in that. So talk to me about what's
17:49
unique about evalise and GLP ones.
17:53
Well, I think about as providers which you can advertise on
17:56
label, not on label. This product right now is the
17:59
only product right now where the label actually recognizes that
18:03
at least filler can be lost, can be used with the patients who
18:07
have the wrinkles and folds that are attributed to weight loss.
18:11
Interesting, interesting. That's great to know because in
18:15
our data and studies, the people that are having and using the
18:20
GLP ones, the first treatment that they're going for is a skin
18:24
tightening or a filler or something to help with what
18:27
happens to their skin as a result of the GLP ones.
18:30
So that's a great story to be able to pair that together.
18:33
So we're excited about that. So you've had Jouvo for how many
18:38
years has it been? So we launched it in 2019 and
18:42
then there was a relaunched it in full.
18:46
But basically we've launched since 2019.
18:49
Yeah, it's like 3 or three years now.
18:51
It's been the fastest growing toxin.
18:53
So for this many years you haven't been in this category.
18:58
So what made this the right time to add to the Juveau popularity?
19:03
If we look at the field of aesthetics, the number one asset
19:07
in that field is a box on toxin, period.
19:09
And the conversation, nothing even close, there's absolutely
19:13
nothing close. So we really, that's why that
19:17
the box on toxin was our first asset, because if you have a box
19:21
on toxin that works, then you can build an asset around that.
19:26
And you know, selling a product and putting the energy into it,
19:31
particular for small company like ours is a really big deal.
19:34
Adding on an HA would be logical because if you look at the top 2
19:39
assets in aesthetics will be HA injectables and botulinum toxic
19:44
became a natural. But I think we've really
19:46
benefited from that singular focus of introducing and
19:50
bringing Java and we did a lot of things that none of our
19:53
competitors did. I think I'd like to be
19:56
complimentary to all the neurotox that are available.
19:58
They work really well. Like if we look at.
20:02
The botulinum toxin as a category, I mean it's amazing.
20:05
That drug works incredibly well. And I think all the
20:07
manufacturers if you're approving the United States have
20:09
a reasonable offering. But you know, when we were
20:12
there, the lion's share was owned by of that market was
20:15
Allergan. And instead of just trying to
20:17
compete against everyone, what we wanted to do was we knew we
20:21
had a really good botulinum toxin.
20:23
We knew we had really good clinical data.
20:25
But what we thought we would do is try and expand the market.
20:28
And so when we when you looked at ours, most people will say
20:33
the market is only about 10% penetrated.
20:35
So we made a concerted effort to really focus on the millennial
20:38
and the millennial now is pushing 40 years of age at that
20:41
lead. So all our marketing material
20:44
and all the stuff that we did was really focused on trying to
20:47
bring in the millennial and published data that actually
20:49
shows this medicine can actually be regenerative.
20:52
You could actually stave off the wrinkling process or even
20:55
reverse it. Phenomenal.
20:57
That's I think that you're definitely on the frontier of
20:59
something absolutely new. And on that topic, do you see
21:04
that Evelise is going to change the way that doctors and
21:08
injectors are going to talk to their patients about filler?
21:13
I, I hope so. Like I said, we were trying to
21:16
drop the F word so that people would just anchor in a
21:18
hyaluronic acid. I think again, just bringing
21:22
back to the tone that AJ fundamental that building bone
21:25
is a natural product. And I think the fact that
21:28
heavily seems to be a really efficient gel in that a little
21:31
bit of material seems to go a long way may very well help that
21:34
narrative. And that's what I was going to
21:35
ask you, You know, what is the positioning, the conversation
21:40
that you're planning to use to set this apart, right?
21:43
Like what is that messaging for customers because the trust is
21:47
built with these other brands? What is the messaging that
21:50
you're going to be using to set everything apart?
21:54
Well, the fundamental building block is the one I can share
21:56
with you if you like a JS natural product and gives you a
21:59
natural look. And on the botulinum toxin side,
22:02
the Gevo, one of the attributes that we're seeing is it's a
22:06
really precise drug and that also fits in with that natural
22:11
theme. With precision, you can get kind
22:15
of a more natural look. So for instance, if you're going
22:17
to do certain areas that precision will give you a more
22:20
subtle look, OK. And I'm looking forward to
22:24
seeing all the marketing behind it.
22:26
I think that in the now the consumer is looking so much more
22:31
for that natural look. So I think that that's going to
22:36
be a great for this time because I do think just a few years ago,
22:40
people wanted this very extreme look, right?
22:43
And so I think that now that we've settled into natural, this
22:46
will go a long way. And one of the things I wanted
22:49
to ask you as we start to wrap things up, looking back on your
22:53
career as the expert in this industry and now that you've
22:57
shared with us where you've been, what you've done,
22:59
obviously you are the expert. What shaped how you approached
23:04
bringing Evelise to market? You know, from all of the
23:07
information and expertise that you've gathered along the way,
23:11
the simplicity was a real big factor.
23:13
If we look at the United States, we have, I'll say kind of two
23:18
dominant families, one from the Galdera line, one from the
23:21
Allergan APFY line. Well deserved.
23:23
You know, they're excellent products.
23:25
If you go to Europe, I mean there are hundreds of fillers,
23:30
Nhas and you may ask, well, what's the difference?
23:33
Well, it's the level of scrutiny to get something approved.
23:37
In Europe. They used to have what was
23:38
called the MDD process and medical directive, and then they
23:42
will move to what was called the MDR.
23:45
And DMDR is basically they go from a medical directive to a
23:49
medical regulation, medical device regulation.
23:52
And in the old days in Europe, you didn't even need clinical
23:56
studies necessarily to get something approved.
23:59
Whereas with this new regulation now you need some sort of
24:02
clinical trial in the United States.
24:05
These products are a device and they're classified as a Class 3.
24:11
And the FDA expects to see a lot of data.
24:14
They want to see, they don't understand the manufacturing,
24:17
the bulk compatibility. They want to see how long stuff
24:20
lasts. They want to see how it performs
24:22
in humans. They want to see both efficacy
24:25
and safety and at a high rigor level.
24:28
So that's the environment that we're in in the United States,
24:32
which I think benefits all of us.
24:34
If I think about why I like Devily so much, it really
24:37
anchors around what I said to you earlier.
24:39
You know, I did practice medicine for 20 years.
24:41
And when I looked at patients, you manage them.
24:44
You want them to have a good outcome and inevitably something
24:47
goes wrong. And when you have to manage an
24:49
adverse event or something that goes wrong, you're the provider
24:53
and it's your patient. So it can't help but feel it a
24:56
little bit personally. And you want patients to have
24:58
good outcomes. And then as somebody who did
25:00
R&D, the thing that I think was most humbling is I saw a lot of
25:03
technologies and worked with a lot of technologies and you go,
25:07
wow, that's amazing. And then as you put them through
25:11
and you get into a bigger enough sample size, you sometimes get
25:15
surprised with one of the outcomes or one of the adverse
25:18
events that you never saw coming.
25:20
And you never forget that. So with new technologies,
25:24
sometimes you can create a new problem and I think we always
25:28
need to be humbled with that. And I think those data points
25:32
for me were why the Sevilleise HHL was resonated with me and
25:38
that was I recognize what the new technology was.
25:42
They basically took a very smart approach to a problematic step
25:48
that cross linking. And then when I thought about
25:51
what is the new chemistry here, when you step back, you go there
25:55
is none. So what they did was just took
26:00
what everyone had been doing and try to fix a problem.
26:03
And that's why it's so appealing to me.
26:05
So far we've been having good results.
26:07
People who can have the clinical studies in the United States
26:09
have borne out that it seems to be a good product.
26:12
But those are the things that you know, make me feel good
26:15
about it and kind of how I was thinking through things.
26:18
And a plug for our CEO, Dave Modazetti, who was also came
26:22
from Allergan. And I love it when he talks
26:25
about, you know, we're a performance beauty company.
26:27
And what we mean by that is we look for products and we always
26:31
want to bring products that are as good as the standard.
26:34
We're always happy to bring something we think that may be
26:36
better and that's how we look at it supposed to just bring a
26:39
product for the sake having something portfolio.
26:41
So I really appreciate his charter and hopefully we're
26:44
living by it. Well, you've done an amazing job
26:49
of filling us in on all things Evolis and Evolise, and we
26:53
appreciate that. And I'm just going to ask one
26:56
more question for our listeners and viewers, because you are the
27:00
expert in our space. What do you think, Doctor
27:03
Avalar, the future of aesthetics holds for us in the next 5 or 10
27:07
years? I think it's bold and very
27:10
positive. We're looking at some of the
27:12
technologies right now that I think there is potential for
27:15
being more creative in the biostimulant area.
27:18
We're looking at things that are really early, such as gene
27:21
therapy. And we know that skin quality as
27:24
we age is something we're trying to impact and we're recognizing
27:27
the roles of various things for that.
27:29
But I look at it from a technology perspective.
27:31
I see various things that can come in.
27:34
I look at the field of biomaterials.
27:37
I believe that there's some innovations coming there
27:39
particular that can impact positively regenerative
27:42
medicine. And as a field, you know, I, I
27:44
think it's really positive. Again, it's not a saturated
27:47
field. Probably again, you hear we're
27:50
only maybe 10% saturated. Here's an interesting stuff that
27:54
I heard about from GLP ones. We know that when you use the
27:57
GLP one, there are a number who then turn to aesthetics because
28:02
as you mentioned that volume loss, that skin and you hear, I
28:06
just have aged prematurely. And so they're looking for
28:10
solution with aesthetics does offer the staff that I didn't
28:14
expect is of the GLP 1 users in this particular survey, 20% of
28:20
them hadn't even heard of the field of aesthetics.
28:24
So there's a whole door opening for some people who didn't even
28:28
know that some of these technologies are around.
28:30
And I think that inspires more investment from the companies
28:34
and just a bigger community that participates.
28:36
And I think that's really good for the industry.
28:39
Well, it sounds like a very exciting time to be in
28:41
aesthetics and you're at the forefront and the experts.
28:44
So thank you so much for joining us today.
28:47
And I think that we are very excited to have this hit the
28:50
market and see how it starts affecting our faces and giving
28:54
us a natural look. So thank you so much, Doctor
28:57
Avalar, thank you so much. My pleasure and thank you for
29:01
joining us today on the show, everyone.
29:03
We look forward to seeing you on the next episode of The Doctor
29:06
Randy Show. Doctor Randy Boyett holds a PhD
29:10
and is a recognized leader in the aesthetics and medical
29:12
industry. She is not a licensed medical
29:15
doctor. All commentary and product
29:17
recommendations are based on industry expertise and are
29:20
provided for informational purposes only.